staceywhite, Author at European Medical Journal - Page 32 of 195

Skin Microbiome and Acne

Marco Rocha, Thomas Dirschka, and Alison Layton discuss the current acne landscape, the potential role of the skin microbiome in acne…

Therapies for AGA

Androgenetic alopecia (AGA) is the leading cause of hair loss in both men and women. Experts outline current and emerging therapies in the…

Tralokinumab in Atopic Dermatitis

To discuss how biologics have disrupted clinical management of atopic dermatitis, and how tralokinumab fits into this paradigm, the EMJ sat…

Therapeutic Advances in GI Cancers: Immuno-Oncology and Beyond

At the 2024 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain, the latest advancements in immunotherapy for…

Remission Without Glucocorticoids as a SLE Treatment Goal

SLE is a chronic and complex heterogeneous autoimmune disease in which the immune system dysfunctions and inappropriately attacks healthy…

31 Oct 2024

Tackling Infectious Diseases

This interactive article summarises key discussions from GSK sponsored symposia that took place during the ESCMID Global Congress 2024, held from 27–30th April 2024 in Barcelona, Spain.

31 Oct 2024

Under the Lens: Progression of Diabetic Retinopathy and the Impact of Fenofibrate

With an increasing prevalence of diabetic retinopathy, a cause of vision impairment and blindness in those with diabetes, there is a need…

Unravelling HER2+ Breast Cancer

A highly engaging infographic providing information on the incidence, diagnosis and treatment options for HER2+ breast cancer. It touches…

ER+/HER2- Metastatic Breast Cancer – Treatment after ET + CDK4/6i

Over 70% of breast cancers are ER+/HER2-, for which the backbone of treatment is ET.1-3 Advanced breast cancer (aBC) can be considered to…

Predisposition, Clinical Characteristics and Management of Immune Checkpoint Inhibitor-Induced Nephritis

Immune checkpoint inhibitors (ICI) use can lead to an array of immune-related adverse events (irAE). Nephritis is considered to be…